ClinicalTrials.gg
CompletedNCT07349381Updated Oct 13, 2026

A Food-Effect Study of CX11 in Healthy Participants

A Phase 1 interventional study of CX11 (VCT220) in Obesity & Overweight and Type 2 Diabetes, sponsored by Vincentage Pharma Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Vincentage Pharma Co., Ltd · Phase 1, Interventional, and Basic science

Updated Oct 13, 2026Now CompletedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 600 studies in Obesity with a site in China — 221 open to participants now, 282 under way, 67 of them phase 3. Obesity · China.

Enrollment
437th of 502
32 · median 120
Started
2026
with 133 others
Phase 1
93 of 600
29 open now
Registered
451st of 600
by date

Among the 600 studies in Obesity with a site in China, this one is the 437th largest by enrollment of the 502 interventional ones that give a count, is one of 134 that started in 2026, is one of 93 in phase 1, and was the 451st registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

221 of the 600 studies in Obesity with a site in China are open now. Recruiting first, the newest first:

216 more — sign in →

All 221 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 600 studies in Obesity with a site in China, or all of them as a file.
02

Study summary

This study is to evaluate the food effect (FE) on the PK of 200 mg CX11 in healthy participants

03

Conditions studied

  • Obesity & Overweight
  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Fully understand the objective, nature, methods, and possible adverse reactions of the study; be able to communicate well with the investigator; voluntarily take part in the study and be willing to comply with the requirements of this study; and sign the form before all study procedures are started
  2. Weight ≥ 50.0 kg for men and ≥ 45.0 kg for women, and (BMI) is ≥ 20.0 kg/m2 and \< 28 kg/m2 at the screening visit and on Day 21.

Exclusion criteria

Exclusion Criteria:

  1. Participants with allergic constitution or known previous history of allergy to CX11 or similar compounds and related , or history of atopic allergic diseases
  2. Participants who have experienced acute diseases during the pre-study screening period or within 2 weeks prior to the first dose of the product
  3. Participants who have pre-existing condition interfering with normal gastrointestinal anatomy or motility, hepatic and/or renal function that could affect drug absorption, distribution, metabolism, and/or excretion as judged by the investigator, or plan to receive any surgery during the study
  4. Participants suffering from any clinically significant chronic diseases, including but not limited to disorders of the respiratory system, cardiovascular system, urinary system, blood system, endocrine system, and immune system, as well as the digestive system (e.g., history of or current fatty liver disease, including metabolic dysfunction-associated steatohepatitis
  5. History of thyroid dysfunction requiring medication or with a thyroid stimulating hormone (TSH) level exceeding the normal reference range at screening or on Day 21
  6. Participants who have been vaccinated within 30 days before the screening or plan to be vaccinated during the study
  7. Participated in any other clinical study and received an investigational intervention within 90 days or 5 elimination half-lives (whichever is longer) of the investigational intervention, prior to screening
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Fasted-Fed Arm

    Fasted-Fed Group

    Drug: CX11 (VCT220)

  • Experimental
    Fed-Fasted Arm

    Fed-Fasted Group

    Drug: CX11 (VCT220)

Interventions

  • CX11 (VCT220) administered orally to participants who are in fasted/fed state in the first 6 consecutive days, and in fed/fasted state on the 7th day

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time curve from 0 to 24 hour (AUC0-24) of CX11 (VCT220)

    AUC0-24 of of CX11 (VCT220)

    Time frame: Predose at Day1 up to 35 days postdose

  2. Maximum Observed Concentration (Cmax) of CX11 (VCT220)

    Cmax of CX11 (VCT220)

    Time frame: Predose at Day1 up to 35 days postdose

  3. Time to Maximum Observed Concentration (Tmax) of CX11 (VCT220)

    Tmax of CX11 (VCT220)

    Time frame: Predose at Day 1 up to 35 days postdose

07

Study locations

1 site
  • Shanghai Xuhui Central Hospital
    Shanghai, Shanghai Municipality, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2026 to primary completion in Jun 2026, 3 months.

Of 334 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 3 months is below that.

Counting every sponsor, half of 439 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Aug 2026, on Oct 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2026
First posted
Jan 16, 2026
StartActual
Mar 4, 2026
Primary completionActual
Jun 30, 2026
CompletionActual
Aug 30, 2026was Sep 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 13, 2026
Study completion
Sep 30, 2026→Aug 30, 2026 (actual)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Active, not recruiting→Completed
    Study completion Sep 30, 2026→Aug 30, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07349381
Lead sponsor
Vincentage Pharma Co., Ltd
Collaborators
Corxel Pharmaceuticals
Responsible party
Sponsor
First posted
Jan 16, 2026
Start date
Mar 4, 2026
Primary completion
Jun 30, 2026
Completion
Aug 30, 2026
Last update
Oct 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CX11

Start the discussion